Errors in Results | Oncology | JAMA Oncology | JAMA Network
[Skip to Navigation]
Sign In
Views 380
Citations 0
Correction
January 2020

Errors in Results

JAMA Oncol. 2020;6(1):162. doi:10.1001/jamaoncol.2019.6325

In the Brief Report titled “Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer,”1 published online August 1, 2019, and in print on October 10, 2019, there were a data errors in the Results section. Validated personalized digital polymerase chain reaction assays were developed for 150 mutations (90.9%), not 91.5%. Of the 29 patients who relapsed, 23 (79.3%), not 88.4%, relapsed with prior circulating tumor DNA detection, whereas 6 (20.7%), not 21.6%, relapsed without circulating tumor DNA detection before or at the time of relapse. This article has been corrected online.

References
1.
Garcia-Murillas  I, Chopra  N, Comino-Méndez  I,  et al.  Assessment of molecular relapse detection in early-stage breast cancer.  JAMA Oncol. 2019;5(10):1473-1478. doi:10.1001/jamaoncol.2019.1838Google ScholarCrossref
×